Airway Epithelial Plasticity in Upper Respiratory Disorders

Abstract

Airway epithelial plasticity is a central feature in the pathogenesis, progression, and therapeutic targeting of various upper respiratory disorders (URDs). This review synthesizes current scientific understanding of epithelial cell adaptability in response to environmental challenges, infection, and inflammation, emphasizing mechanistic insights and clinical outcomes. Recent evidence highlights the dynamic remodeling of epithelial phenotypes, the role of epithelial–mesenchymal transition (EMT), and the impact on disease burden, risk stratification, and management. Clinicians are guided on diagnostic, prognostic, and therapeutic aspects, with a focus on guideline-based and emerging strategies to optimize patient outcomes.

Introduction

The upper respiratory tract is lined by a specialized airway epithelium that serves as both a physical and immunological barrier, maintaining homeostasis and host defense. In upper respiratory disorders such as chronic rhinosinusitis (CRS), allergic rhinitis (AR), and non-allergic rhinitis, the airway epithelium exhibits remarkable plasticity defined as its ability to adapt and remodel in response to environmental, infectious, and inflammatory stimuli. This plasticity can be protective or maladaptive, influencing disease onset, severity, chronicity, and response to therapies. Understanding epithelial plasticity is increasingly recognized as fundamental for advancing the management of upper respiratory diseases in clinical practice.

Epidemiology / Disease Burden

Upper respiratory disorders represent a substantial global health challenge, affecting hundreds of millions of individuals annually. Chronic rhinosinusitis affects up to 12% of the adult population worldwide, while allergic rhinitis prevalence ranges from 10% to 40%, with significant regional variation. These conditions contribute to reduced quality of life, absenteeism, and economic burden. Epithelial plasticity, through mechanisms such as loss of barrier integrity, goblet cell hyperplasia, and squamous metaplasia, is implicated in both the initiation and perpetuation of URDs. The high recurrence rate and chronicity in URDs are closely tied to maladaptive epithelial remodeling, underscoring the need to address this phenomenon in both research and clinical settings.

Pathophysiology

The airway epithelium comprises ciliated, goblet, and basal cells, all of which contribute to mucociliary clearance and innate immunity. Epithelial plasticity is orchestrated by a complex interplay of genetic, epigenetic, and environmental factors. Upon exposure to allergens, pathogens, pollutants, or injury, epithelial cells may undergo dedifferentiation, proliferation, and differentiation into alternative phenotypes. Key mechanisms include epithelial–mesenchymal transition (EMT), upregulation of transcription factors such as Snail and Twist, and activation of signaling pathways like TGF-β, Wnt, and Notch. These changes may result in impaired barrier function, increased permeability, and aberrant repair, contributing to chronic inflammation, tissue remodeling, and polyp formation in diseases such as CRS and AR. The plasticity of the epithelium also affects the recruitment and activation of immune cells via altered cytokine and chemokine profiles, further sustaining the inflammatory milieu.

Risk Factors

Several risk factors contribute to the induction and persistence of epithelial plasticity in URDs. Genetic predisposition, including polymorphisms in genes regulating epithelial integrity and repair, increases susceptibility. Environmental exposures such as tobacco smoke, air pollution, occupational irritants, and recurrent viral or bacterial infections serve as potent triggers for epithelial remodeling. Allergic sensitization and comorbid conditions like asthma further exacerbate epithelial dysfunction. Notably, impaired epithelial repair mechanisms and persistent EMT are observed more frequently in patients with severe or refractory disease phenotypes, highlighting the interplay between host factors and environmental insults.

Clinical Features

Clinical manifestations of URDs with prominent epithelial plasticity include persistent nasal obstruction, rhinorrhea, anosmia, facial pain, and pressure. In CRS with nasal polyps, epithelial remodeling manifests as polypoid lesions, while in AR, goblet cell hyperplasia leads to excessive mucus production. Chronicity and recurrence are hallmarks of cases with significant epithelial remodeling. The loss of ciliated cells and increased permeability predispose to recurrent infections and secondary bacterial colonization. In some instances, squamous metaplasia may occur, particularly in response to chronic irritant exposure, further compromising mucociliary clearance and barrier function.

Diagnosis

Diagnosis of upper respiratory disorders with epithelial involvement relies on a combination of clinical evaluation, endoscopic examination, and imaging studies such as CT or MRI to assess mucosal thickening and polyp formation. Histopathological analysis of nasal or sinus biopsies may reveal features indicative of epithelial plasticity, including loss of cilia, goblet cell metaplasia, basement membrane thickening, and evidence of EMT. Advanced molecular diagnostics including immunohistochemistry for epithelial and mesenchymal markers, as well as biomarker profiling of nasal secretions are increasingly used in research settings to stratify patients and monitor disease progression.

Treatment & Management

Therapeutic strategies in URDs target both inflammation and epithelial dysfunction. Intranasal corticosteroids remain the cornerstone of management, exerting anti-inflammatory and anti-remodeling effects by modulating cytokine release and reducing epithelial hyperplasia. In refractory cases, systemic corticosteroids, leukotriene receptor antagonists, and macrolide antibiotics may be employed. Allergen immunotherapy is effective in AR, potentially restoring epithelial barrier function. Surgical intervention (e.g., functional endoscopic sinus surgery) is reserved for severe cases with extensive polypoid changes or anatomical obstruction. Barrier-enhancing agents and mucolytic therapies are under investigation for their potential to directly improve epithelial function.

Recent Advances / Emerging Therapies

Recent advances focus on targeting the molecular drivers of epithelial plasticity. Biologic agents such as anti-IL-5 (mepolizumab), anti-IL-4Rα (dupilumab), and anti-TSLP therapies have demonstrated efficacy in reducing polyp burden and improving symptoms in CRS and AR by modulating type 2 inflammatory pathways and restoring epithelial homeostasis. Small molecule inhibitors targeting TGF-β and related EMT pathways show promise in preclinical studies. Regenerative medicine approaches, including stem cell therapy and tissue engineering, aim to restore normal epithelial architecture. Ongoing clinical trials are evaluating the long-term safety and efficacy of these novel interventions, with a focus on personalized medicine approaches based on molecular endotyping.

Guideline Recommendations

Clinical practice guidelines from organizations such as the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and the American Academy of Otolaryngology-Head and Neck Surgery emphasize the importance of accurate phenotyping, early intervention, and multimodal therapy in the management of URDs. Recent updates underscore the need for routine assessment of epithelial health, identification of high-risk individuals, and consideration of biologic therapies in severe, refractory cases. Personalized approaches incorporating molecular diagnostics and patient-specific risk factors are increasingly advocated to improve outcomes and minimize disease recurrence.

Conclusion

Airway epithelial plasticity plays a pivotal role in the pathogenesis and clinical course of upper respiratory disorders. Advances in molecular and translational research have deepened our understanding of the mechanisms underlying epithelial remodeling and have paved the way for targeted, mechanism-based therapies. Clinicians should remain vigilant for signs of maladaptive epithelial plasticity and incorporate recent guideline recommendations and emerging therapies into practice to optimize patient care. Continued research into epithelial biology and its clinical implications will be essential for reducing the burden of URDs and improving quality of life for affected individuals.